Cancer incidence rate of 3%
The morning of May 21, represent the highest level of medical anti-cancer Chinese Journal of Academic Assembly at its sixth meeting in Shanghai. The conference theme is "Science and anti-cancer, Better Life", including at home and abroad, Hong Kong, Macao and Taiwan Region in 4000 cancer specialists attended the meeting, participants called for oncologists, cancer therapy should strengthen the "scientific treatment" of thinking, to avoid "blanket" treatment model of unification. In the "common treatment" mode highlight the individual differences.
Press conference was informed that the incidence of getting younger and younger cancer, gastric cancer, breast cancer and other diseases easily become young men and women, cancer death of adult women, 16% are caused by breast cancer, anti-cancer drugs in the market demand for long-term "hunger state." The global pharmaceutical giant, Novartis seize the opportunity to move anti-cancer weapon bright, "Felon," this oral aromatase inhibitor, with a focus postmenopausal receptor-positive breast cancer treatment.
Annual surge in the incidence of internal tumors -5% 3%
At the meeting, Chinese Anti-Cancer Association, Chinese Academy of Engineering, said Professor Hao Xishan, China's annual cancer incidence rate of 3% to 5% of the rate increase, each year, 80% of new tumors in China India, Brazil and other developing countries.
Related survey among our city the highest incidence of male cancer, lung cancer, gastric cancer, liver cancer, while women with breast cancer led.
Fudan University Cancer Hospital Professor Shao Zhimin introduced to Shanghai, for example, the incidence of breast cancer has been ranked for 15 consecutive years, the first female malignancy. According to Guangdong Provincial Hospital of
Fangcun Branch, director of Zhong Shaowen introduction of breast, cancer has become the best workforce in China caused the loss, medical costs, a major reason. However, domestic Cancer is still not standardized, long-term anti-cancer drugs in a "hunger state", early detection, early diagnosis, early treatment is far from the goal to achieve. Tool for breast cancer
eyes wide smoking "The West as a higher incidence of breast cancer, larger R & D investment, new drug after another. In China, before more emphasis on pre-operative chemotherapy, endocrine therapy for the past ten years, mainly Zeyi." According to Zhong Shaowen introduction, tamoxifen is The first endocrine therapy, aromatase inhibitors currently dominated by its main principle is to reduce estrogen levels, thus inhibiting the formation of aromatase, the final inhibition of tumor growth. Such as Femara (letrozole) for postmenopausal, receptor-positive women can be safe to use, "with tamoxifen monotherapy compared Femara monotherapy proved to be a long-term improvement of disease-free survival and lower the risk of distant spread of the disease, can significantly improve the overall survival of 17%. " At present, the drug has been sold in more than 100 countries.
According to reports, after the initial surgery (adjuvant) treatment, the risk of distant recurrence after surgery usually peak two to three years, but from the BIG1-98 study of single-drug therapy group, has been shown Compared with tamoxifen, aromatase inhibitors, significantly lower in postmenopausal patients with hormone-sensitive early breast cancer recurrence risk after surgery, which, compared with tamoxifen, Femara reduced the risk of overall recurrence of 19%, lower 27% risk of distant metastasis.
I am a professional writer from China Computer Parts, which contains a great deal of information about sohc turbo kit , acura throttle body, welcome to visit!
Processing your request, Please wait....
